T-cell immunotherapy: Looking forward Journal Article


Authors: Corrigan-Curay, J.; Kiem, H. P.; Baltimore, D.; O'Reilly, M.; Brentjens, R. J.; Cooper, L.; Forman, S.; Gottschalk, S.; Greenberg, P.; Junghans, R.; Heslop, H.; Jensen, M.; Mackall, C.; June, C.; Press, O.; Powell, D.; Ribas, A.; Rosenberg, S.; Sadelain, M.; Till, B.; Patterson, A. P.; Jambou, R. C.; Rosenthal, E.; Gargiulo, L.; Montgomery, M.; Kohn, D. B.
Article Title: T-cell immunotherapy: Looking forward
Abstract: The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. "T Cell Immunotherapy: Optimizing Trial Design," a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach. © The American Society of Gene & Cell Therapy.
Journal Title: Molecular Therapy
Volume: 22
Issue: 9
ISSN: 1525-0016
Publisher: Nature Publishing Group  
Date Published: 2014-09-01
Start Page: 1564
End Page: 1574
Language: English
DOI: 10.1038/mt.2014.148
PROVIDER: scopus
PUBMED: 25186558
PMCID: PMC4435492
DOI/URL:
Notes: Export Date: 1 October 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Michel W J Sadelain
    583 Sadelain